Compare Lithium Americas Corp (LAC) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lithium Americas Corp vs ResMed Inc. — how do they compare? Lithium Americas Corp trades at $3.03 (market cap $1.01B), while ResMed Inc. trades at $196.16 (market cap $28.81B). The key difference: ResMed Inc. is far larger — about 28.5× Lithium Americas Corp's market cap, and ResMed Inc. pays a 1.21% dividend while Lithium Americas Corp pays none. Which is the better fit depends on your goals.
| LAC | RMD | |
|---|---|---|
Market Cap | $1.01B | $28.81B |
Sector | Basic Materials | Health |
52-Week High | $10.05 | $293.73 |
52-Week Low | $2.55 | $182.82 |
Enterprise Value | $1.13B | $27.99B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lithium Americas (LAC) trades at $2.90, down 1.69% amid bearish technical signals despite recent earnings beats. The company shows negative profitability with ROE at -11.35% and net income of -$122.09M for 2025, though it maintains strong financing cash flow of $1.14B. Construction milestones at Thacker Pass project progress, with 2026 expected to be pivotal for operational developments according to company guidance.
Investment outlook balances significant project potential against substantial execution risks. While analyst consensus leans positive with 47% buy ratings and no sell recommendations, the stock faces headwinds from negative cash flow from operations and high capital expenditure requirements. Key risks include dilution from share issuances and sensitivity to lithium market dynamics.
ResMed (RMD) trades at $198.61, down 0.19% on the day, with a neutral technical signal and bearish moving averages. The company shows strong fundamentals, with Q1 2026 EPS beating estimates at $2.86 and revenue growth from $5.15B in 2025 to a projected $5.5B in 2026. Recent news highlights the sale of its MatrixCare business for $490 million, sharpening focus on core sleep and respiratory care markets. Analyst consensus is a Buy with a $245.88 price target, implying significant upside.
The outlook for RMD is positive, driven by consistent earnings beats, robust cash flow growth, and strategic divestitures. Key opportunities include market leadership in sleep apnea and digital health innovation. Risks involve competitive pressures from GLP-1 drugs and macroeconomic headwinds. Institutional sentiment is mixed but leans bullish on long-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Lithium Americas Corp
Lithium Americas is a resource company focused on developing the Thacker Pass project in Nevada, the largest known lithium resource in the US. It aims to become a major supplier for the electric vehicle battery market.
Read more on LAC →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
